TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

Lecanemab, which has been shown to target and remove beta-amyloid plaques, has been approved by the U.S. Food and Drug Administration to treat AD early in the disease's progression.

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, the drugs boost levels of a healthy form of amyloid beta (Aβ42 ...

What if your doctor could, when you turn 65, order a test that predicts whether you are going to develop Alzheimer’s dementia in your 70s or 80s? And what if – in case the test comes back ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting brain protein amounts may offer cognitive benefits.

For people newly diagnosed with early-stage Alzheimer’s disease, donanemab and lecanemab offer hope by slowing cognitive decline. These medications work by removing beta-amyloid plaques in the ...

Alzheimer's disease is likely caused by stalled protein processing in the brain, according to a new study. The research, published today in eLife, is described by editors as a fundamental study ...

High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations. Journal of Alzheimer's disease : JAD, 90 (1), 333–348. https://doi ...

Lecanemab’s Positive Opinion from the CHMP in the European Union was primarily based on Phase 3 data from Eisai’s global Clarity AD clinical trial, in which it met its primary endpoint and all ...